Long-term Follow-up Study of COVID-19
Long-term Large Sample Multicenter Follow-up Study of COVID-19
1 other identifier
observational
5,700
1 country
2
Brief Summary
The goal of this observational study is to learn the long-term prognosis of patients and the clinical characteristics of complications, which is of great significance for treatment of novel coronavirus infection pneumonia. This trial plans to include 5700 inpatients with positive SARS CoV-2 nucleic acid test results. This trial does not involve the use of specific drug. Participants's health and psychological status will be observed at the preset time points. The blood, feces, urine samples of patients will be collected for relevant tests.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2020
Typical duration for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 20, 2020
CompletedFirst Submitted
Initial submission to the registry
August 8, 2023
CompletedFirst Posted
Study publicly available on registry
August 14, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2023
CompletedAugust 14, 2023
July 1, 2023
3.2 years
August 8, 2023
August 8, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
clinical manifestation
3 months, 6 months, 12 months, 18 months, 24 months, 36 months after patients discharge
Secondary Outcomes (9)
psychological status
3 months, 6 months, 12 months, 18 months, 24 months, 36 months after patients discharge
quality of life scores
3 months, 6 months, 12 months, 18 months, 24 months, 36 months after patients discharge
cranial imaging results
3 months, 6 months, 12 months, 18 months, 24 months, 36 months after patients discharge
lung imaging results
3 months, 6 months, 12 months, 18 months, 24 months, 36 months after patients discharge
cytokines level
3 months, 6 months, 12 months, 18 months, 24 months, 36 months after patients discharge
- +4 more secondary outcomes
Eligibility Criteria
The inpatients with positive SARS CoV-2 nucleic acid test results will be included.
You may qualify if:
- Patients with confirmed COVID-19
You may not qualify if:
- Combined infection with influenza virus, mycoplasma, and chlamydia.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Tongji Hospitallead
Study Sites (2)
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
Wuhan, Hubei, China
Wuhan Seventh Hospital
Wuhan, Hubei, China
Biospecimen
There are many patients who are prospectively observed. Their samples will be collected. The samples will include blood, urine, throat swabs etc.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Qin Ning, Professor
Tongji Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director, department of infection
Study Record Dates
First Submitted
August 8, 2023
First Posted
August 14, 2023
Study Start
October 20, 2020
Primary Completion
December 31, 2023
Study Completion
December 31, 2023
Last Updated
August 14, 2023
Record last verified: 2023-07